BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35698180)

  • 1. Prognostic and tumor immunity implication of inflammatory bowel disease-associated genes in colorectal cancer.
    Wang D; Xie B
    Eur J Med Res; 2022 Jun; 27(1):91. PubMed ID: 35698180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the glycolytic cross-talk genes between inflammatory bowel disease and colorectal cancer.
    Ye C; Huang Y; Gao Y; Zhu S; Yuan J
    Funct Integr Genomics; 2023 Jul; 23(3):230. PubMed ID: 37428395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of m6A-Related Biomarkers Associated with Prognosis of Colorectal Cancer.
    Zhang Z; Zhang X
    Med Sci Monit; 2021 Aug; 27():e932370. PubMed ID: 34373442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
    Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
    Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.
    Hou Y; Zhang R; Zong J; Wang W; Zhou M; Yan Z; Li T; Gan W; Lv S; Zeng Z; Yang M
    Front Immunol; 2022; 13():892512. PubMed ID: 35711437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a five-gene signature with prognostic value in colorectal cancer.
    Sun G; Li Y; Peng Y; Lu D; Zhang F; Cui X; Zhang Q; Li Z
    J Cell Physiol; 2019 Apr; 234(4):3829-3836. PubMed ID: 30132881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
    Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
    Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated Profiling Identifies
    Shi J; Bao M; Wang W; Wu X; Li Y; Zhao C; Liu W
    Front Immunol; 2021; 12():722807. PubMed ID: 34646265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma.
    Qiu C; Shi W; Wu H; Zou S; Li J; Wang D; Liu G; Song Z; Xu X; Hu J; Geng H
    Front Immunol; 2021; 12():769685. PubMed ID: 35003085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A signature based on 11 autophagy genes for prognosis prediction of colorectal cancer.
    Chen S; Wang Y; Wang B; Zhang L; Su Y; Xu M; Zhang M
    PLoS One; 2021; 16(10):e0258741. PubMed ID: 34699544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A five-immune-related genes-based prognostic signature for colorectal cancer.
    Zhu L; Wang H; Wang Z
    Int Immunopharmacol; 2020 Nov; 88():106866. PubMed ID: 32781411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry.
    Adams SV; Ahnen DJ; Baron JA; Campbell PT; Gallinger S; Grady WM; LeMarchand L; Lindor NM; Potter JD; Newcomb PA
    World J Gastroenterol; 2013 Jun; 19(21):3241-8. PubMed ID: 23745025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?
    Breynaert C; Vermeire S; Rutgeerts P; Van Assche G
    Acta Gastroenterol Belg; 2008; 71(4):367-72. PubMed ID: 19317276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer.
    Yang X; Wei Y; Sheng F; Xu Y; Liu J; Gao L; Yang J; Sun X; Huang J; Guo Q
    Aging (Albany NY); 2021 Jul; 13(13):17548-17567. PubMed ID: 34233297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
    Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
    Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer.
    Lin K; Huang J; Luo H; Luo C; Zhu X; Bu F; Xiao H; Xiao L; Zhu Z
    Aging (Albany NY); 2020 Mar; 12(7):5832-5857. PubMed ID: 32235004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.